Literature DB >> 8172827

Interleukin-7, interleukin-8, soluble TNF receptor, and p53 protein levels are elevated in the serum of patients with Hodgkin's disease.

L Trümper1, W Jung, G Dahl, V Diehl, A Gause, M Pfreundschuh.   

Abstract

In a search for specific serum markers with prognostic impact, we evaluated the clinical significance of IL-4, IL-7, and IL-8 as well as TNF receptor levels and soluble p53 in the serum of patients with untreated Hodgkin's lymphoma (HD). No elevations were observed for IL-4, while IL-7 and IL-8 were elevated in 15/52 (29%) and 21/78 (27%) patients, respectively. Soluble TNF receptors were detected in 16/29 patients (55%), and were significantly elevated in 6 (21%). P53 was detected in 21/33 (64%) patients. While IL-7 levels, detectable sTNF receptors, and p53 were not correlated with other obvious parameters, elevated IL-8 levels were associated with the presence of B symptoms (p < 0.002) and occurred more often in the nodular sclerosis form than in other histological subtypes (p < 0.02). Further investigations that correlate these serum parameters with the situation at the cellular level of an involved tissue will help to elucidate the enigmatic biology of HD.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8172827     DOI: 10.1093/annonc/5.suppl_1.s93

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  10 in total

1.  Variations in serum IL-7 and 90K/Mac-2 binding protein (Mac-2 BP) levels analysed in cohorts of HIV-1 patients and correlated with clinical changes following antiretroviral therapy.

Authors:  E C Darcissac; V Vidal; X De La Tribonniere; Y Mouton; G M Bahr
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

2.  Discriminant analysis involving serum cytokine levels and prediction of the response to therapy of patients with Hodgkin lymphoma.

Authors:  Maria Kowalska; Joanna Tajer; Magdalena Chechlinska; Malgorzata Fuksiewicz; Beata Kotowicz; Małgorzata Syczewska; Jan Walewski; Janina Kaminska
Journal:  Tumour Biol       Date:  2012-06-08

Review 3.  Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.

Authors:  Rajendra Gharbaran
Journal:  Tumour Biol       Date:  2016-06-18

Review 4.  Hodgkin disease and the role of the immune system.

Authors:  Alana A Kennedy-Nasser; Patrick Hanley; Catherine M Bollard
Journal:  Pediatr Hematol Oncol       Date:  2011-04       Impact factor: 1.969

5.  Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer.

Authors:  Chantal Mengus; Clémentine Le Magnen; Emanuele Trella; Kawa Yousef; Lukas Bubendorf; Maurizio Provenzano; Alexander Bachmann; Michael Heberer; Giulio C Spagnoli; Stephen Wyler
Journal:  J Transl Med       Date:  2011-09-26       Impact factor: 5.531

Review 6.  Biomarkers of gene expression: growth factors and oncoproteins.

Authors:  P W Brandt-Rauf
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

7.  p53 protein is absent from the serum of patients with lung cancer.

Authors:  M A Levesque; M D'Costa; E P Diamandis
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

8.  Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia.

Authors:  Frederique Ponchel; Robert J Verburg; Sarah J Bingham; Andrew K Brown; John Moore; Andrew Protheroe; Kath Short; Catherine A Lawson; Ann W Morgan; Mark Quinn; Maya Buch; Sarah L Field; Sarah L Maltby; Aurelie Masurel; Susan H Douglas; Liz Straszynski; Ursula Fearon; Douglas J Veale; Poulam Patel; Dennis McGonagle; John Snowden; Alexander F Markham; David Ma; Jacob M van Laar; Helen A Papadaki; Paul Emery; John D Isaacs
Journal:  Arthritis Res Ther       Date:  2004-11-16       Impact factor: 5.156

9.  p53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer.

Authors:  J Schneider; P Presek; A Braun; P Bauer; N Konietzko; B Wiesner; H J Woitowitz
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

10.  Clinical Response to the CD95-Ligand Inhibitor Asunercept Is Defined by a Pro-Inflammatory Serum Cytokine Profile.

Authors:  Aleksandar Radujkovic; Tobias Boch; Florian Nolte; Daniel Nowak; Claudia Kunz; Alexandra Gieffers; Carsten Müller-Tidow; Peter Dreger; Wolf-Karsten Hofmann; Thomas Luft
Journal:  Cancers (Basel)       Date:  2020-12-08       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.